American Gene Technologies To Attend 2019 J.P. Morgan Healthcare Conference
ROCKVILLE, MD, UNITED STATES, January 7, 2019 /EINPresswire.com/ — American Gene Technologies announced today that its Chief Executive Officer, Jeff Galvin, will attend the annual J.P. Morgan Healthcare Conference, held at the Westin St. Francis between January 7-10 in San Francisco, California. American Gene Technologies invitation to attend the conference follows recent discussions with J.P. Morgan and other biotechnology…
Read MoreAmerican Gene Technologies Granted FDA Orphan Drug Designation For Phenylketonuria
ROCKVILLE, MD, UNITED STATES, October 18, 2018 /EINPresswire.com/ — American Gene Technologies (AGT), a leading gene and cell therapy company in the discovery and development of lentiviral vector based therapeutics, announces that the U.S. Food and Drug Administration (FDA) received orphan-drug designation #DRU-2018-6572 for the treatment of phenylketonuria (PKU) using its proprietary, lentiviral vector based technology.…
Read MoreAmerican Gene Technologies to Present at 2018 Cell and Gene Meeting On The Mesa
ROCKVILLE, MD, UNITED STATES, September 26, 2018 /EINPresswire.com/ — American Gene Technologies announced today that its Chief Science Officer C. David Pauza, Ph.D. will present at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa to be held October 3-5 in La Jolla, California. Dr. Pauza’s presentation will cover recent progress on AGT’s HIV cure and…
Read MoreImmunotherapy CEO Jeff Galvin Joins The Board of Directors of the Cancer Support Community
ROCKVILLE, MD, UNITED STATES, September 6, 2018 /EINPresswire.com/ — Jeff Galvin, a former Silicon Valley CEO, and now a leader in the field of gene and cell therapy to cure cancer and other human diseases, has joined the Board of Directors of the Cancer Support Community (CSC). Galvin’s biotech company, American Gene Technologies International Inc. (AGT), is striving to…
Read MoreAmerican Gene Technologies (AGT) Granted Three New Patents in its HIV Cure and Immuno-oncology Programs
ROCKVILLE, MD, UNITED STATES, August 22, 2018 /EINPresswire.com/ — AGT announces the receipt of three foundational patents. Two new patents focus on the immuno-oncology program and add to AGT’s broad protection for its unique process of activating gamma delta T cells to attack solid tumors (“Methods and Composition for the Activation of Gamma Delta T…
Read MoreAmerican Gene Technologies CEO Jeff Galvin Joins Maryland Tech Council Board of Directors
ROCKVILLE, MD, UNITED STATES, August 20, 2018 /EINPresswire.com/ — American Gene Technologies International Inc. (AGT)’s CEO and founder Jeff Galvin has been appointed to the Board of Directors of the Maryland Tech Council, the largest Maryland technology trade association, representing over 600 companies across the breadth of technology and life science industries. Galvin stated: “I…
Read MoreAmerican Gene Technologies Congratulates Robert Redfield, M.D., on His Appointment as Director of the Centers for Disease Control and Prevention
ROCKVILLE, Md., March 28, 2018 (GLOBE NEWSWIRE) — American Gene Technologies International Inc. (AGT), a leading gene and cell therapy company, today congratulates Robert R. Redfield, M.D., on his appointment as the Director of the Centers for Disease Control and Prevention (CDC). Dr. Redfield has served as an advisor to AGT since 2011 and later became chair…
Read MoreAmerican Gene Technologies Announces Progress toward Phase I Clinical Trial of AGT103-T for HIV cure
Completes process development for the AGT103-T automated cell manufacturing protocol ROCKVILLE, MD, January 25, 2018 — American Gene Technologies International Inc. (AGT), a leading gene and cell therapy company, today announced completion of the pilot runs of its HIV cure automated cell processing protocol. This completes a key milestone of AGT’s planned Phase I clinical trial…
Read MoreAGT CSO, David Pauza, to Present HIV cure data At The Cell & Gene Meeting on the Mesa
ROCKVILLE, MD., September. 26, 2017 (GLOBE NEWSWIRE) — American Gene Technologies International Inc. (AGT), a gene technology company focusing on a lentiviral delivery platform, today announced that Chief Science Officer C. David Pauza, Ph.D., will present at the upcoming Cell & Gene Meeting on the Mesa being held from October 4-6, 2017, in La Jolla, CA.…
Read MoreAGT Builds Montgomery County Gene & Cell Therapy Momentum
Fast Growing Maryland Biotech Company Moves to a 24,000 Sq. Ft. Location and Will Host Ribbon Cutting Ceremony on October 23, 2017. September 25, 2017. Montgomery County, MD: American Gene Technologies (AGT), a private Maryland biotechnology company developing cures and treatments for Infectious diseases, cancers and monogenic disorders, will celebrate the grand opening of its new 24,000 sq.…
Read MoreAmerican Gene Technologies Inc. Appoints Julia R. Brown to its Board of Directors
ROCKVILLE, Md., Sept. 11, 2017 (GLOBE NEWSWIRE) — American Gene Technologies International Inc. (AGT), a leading gene and cell therapy company with a broad and robust lentiviral drug-development platform, today announced the appointment of Julia R. Brown to its board of directors. Jeffrey A. Galvin CEO and Founder “We are excited to announce Julia’s appointment…
Read MoreAGT CEO, Jeff Galvin, to Present at HIMSS Precision Medicine Summit
ROCKVILLE, MD, May 31, 2017 — American Gene Technologies International Inc. (AGT), a gene technology company with a broad and robust lentiviral delivery platform, today announced that Jeff Galvin, CEO, will present at the upcoming Health Information Management System Society (HIMSS) Precision Medicine Summit, being held from June 12-13, 2017, in Boston. Mr. Galvin will…
Read More